Physician profile
Devang Sharma
NPI 1114346004
$11,673.43
in general payments reported to CMS, 2019-2025
38 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $1,495 · 2021: $1,128 · 2022: $1,432 · 2023: $2,120 · 2024: $3,178 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,943 · Travel and Lodging: $460 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,942.96 |
| Travel and Lodging | $459.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,466.25 | 2021-2025 | Urolift, Barrigel, Deknatel |
| Boston Scientific Corporation | $2,143.47 | 2020-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Spaceoar Vue System - 10ml |
| Coloplast Corp | $1,637.21 | 2019-2024 | Porges Coloplast |
| Dornier Medtech America, INC | $503.10 | 2023 | Dornier Medtech |
| Endo Pharmaceuticals INC. | $485.31 | 2019-2024 | Xiaflex, Aveed, Edex |
| Urogen Pharma, INC. | $458.36 | 2021-2025 | Jelmyto |
| Antares Pharma, INC. | $393.90 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $363.90 | 2020-2025 | Myrbetriq, Veozah, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $340.40 | 2022-2025 | |
| Endo USA, INC. | $312.50 | 2024-2025 | Xiaflex, Aveed, Edex |
| Sumitomo Pharma America, INC. | $293.22 | 2024-2025 | Orgovyx, Gemtesa |
| Axonics, INC. | $217.75 | 2022-2024 | Axonics |
| Abbvie INC. | $205.80 | 2022-2025 | Botox, Lupron Depot |
| Olympus America INC. | $200.62 | 2023-2025 | Itind System |
| Tolmar, INC. | $194.44 | 2023-2025 | Eligard, Jatenzo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devang Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.